MK-8776

DB11899InvestigationalSmall molecule

Sch 900776 has been used in trials studying the treatment of Neoplasms, Hodgkin Disease, Adult Erythroleukemia, Lymphoma, Non-Hodgkin, and Myelogenous Leukemia, Acute, among others.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase Chk1
Curator reviewed
Formula / weight: C₁₅H₁₈BrN₇ · 376.262 g/mol (avg)
Code names: SCH 900776

Resolves to

Compound

UNIIK2ZSF0992CCAS891494-63-6ChEMBLCHEMBL2386889PubChem46239015

Structure

InChIKeyGMIZZEXBPRLVIV-SECBINFHSA-NSMILESCN1C=C(C=N1)C1=C2N=C([C@@H]3CCCNC3)C(Br)=C(N)N2N=C1

Targets

O14757CHEK1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with MK-8776, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account